Valuation: Cipher Pharmaceuticals Inc.

Market Cap 451M 321M 279M 261M 239M 30.62B 457M 3.06B 1.2B 15.3B 1.21B 1.18B 50.93B P/E 2026 *
14.5x
P/E 2027 * 12.9x
Enterprise Value 451M 321M 279M 261M 239M 30.62B 457M 3.06B 1.2B 15.3B 1.21B 1.18B 50.93B EV / Sales 2026 *
6.17x
EV / Sales 2027 * 5.34x
Free-Float
57.65%
Yield 2026 *
-
Yield 2027 * -
1 day-0.85%
1 week+4.58%
Current month+4.58%
1 month+1.56%
3 months-1.51%
6 months+20.63%
Current year+16.87%
1 week 16.85
Extreme 16.85
18.46
1 month 16.1
Extreme 16.1
18.46
Current year 14.2
Extreme 14.2
20.56
1 year 12.48
Extreme 12.48
20.56
3 years 3.35
Extreme 3.35
20.56
5 years 1.54
Extreme 1.54
20.56
10 years 0.38
Extreme 0.38
20.56
Manager TitleAgeSince
Chief Executive Officer - 2019-07-28
Director of Finance/CFO - 2024-08-09
Director of Finance/CFO - 2022-08-14
Director TitleAgeSince
Chairman - 2019-06-11
Director/Board Member 78 2023-06-20
Director/Board Member - 2023-06-20
Date Insider Type Main position Quantity % Market Cap.
6/24/26 Option

Director

2,500 0.0098%
3/20/26 Option

Chairperson

4,180 0.0165%
1/5/26 TaxCompany 95,454 0.3763%
Change 5-day change 1-year change 3-year change Capi.($)
-0.85%+4.58%+29.99%+411.63% 321M
-0.11%+3.46%+85.47%+161.76% 1,062B
-0.08%+0.20%+49.75%+48.39% 619B
+0.09%-2.65%+22.85%+62.51% 431B
+1.22%+4.89%+48.90%+40.04% 358B
+0.79%-0.17%+35.82%+40.66% 293B
+0.72%-5.26%+9.30%+9.94% 247B
+0.27%+5.65%+42.93%+60.88% 219B
+4.45%-0.59%-1.34%-44.16% 200B
+1.10%+1.70%+20.09%+64.16% 162B
Average +0.77%-0.93%+34.37%+85.58% 359.26B
Weighted average by Cap. +0.51%-0.83%+48.48%+75.85%

Financials

2026 *2027 *
Net sales 73.13M 52.11M 45.22M 42.35M 38.74M 4.96B 74.08M 495M 194M 2.48B 196M 191M 8.26B 84.52M 60.23M 52.27M 48.94M 44.77M 5.74B 85.63M 573M 225M 2.87B 226M 221M 9.54B
Net income 30.44M 21.69M 18.83M 17.63M 16.13M 2.07B 30.84M 206M 80.93M 1.03B 81.45M 79.68M 3.44B 36.1M 25.72M 22.32M 20.9M 19.12M 2.45B 36.57M 245M 95.97M 1.22B 96.58M 94.48M 4.07B
Net Debt - -
Logo Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products, manages the required clinical development and regulatory approval process, and markets those products either directly or indirectly in Canada, the United States and South America. The Company's product categories include dermatology, hospital acute care, out‑licensed, and specialty medicine. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Absorica (isotretinoin) is an oral retinoid. Durela, its specialty medicine, is an opioid analgesic indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more. Its pipeline products include Piclidenoson CF-101, MOB-015 and DTR-001.
Employees
5
Date Price Change Volume
26-08-07 $17.60 -0.85% 9,425
26-08-06 $17.75 +4.91% 28,231
26-08-05 $16.92 -0.88% 11,948
26-08-04 $17.07 +1.43% 31,578
26-07-31 $16.83 +2.25% 32,197
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
17.75CAD
Average target price
20.64CAD
Spread / Average Target
+16.27%

Quarterly revenue - Rate of surprise